• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc. (Amendment)

    2/13/24 5:01:04 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email
    SC 13G/A 1 tv0437-biomarinpharmaceutica.htm SCHEDULE 13G/A biomarinpharmaceuticalinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  BioMarin Pharmaceutical Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  09061G101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  09061G101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    127,330

    7.  SOLE DISPOSITIVE POWER

    17,621,678

    8.  SHARED DISPOSITIVE POWER

    426,879

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    18,048,557

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.58%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    BioMarin Pharmaceutical Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    770 Lindaro Street
    San Rafael, CA 94901

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    09061G101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $BMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    5/19/2026$75.00Buy
    Citigroup
    5/11/2026$69.00Neutral
    Goldman
    4/27/2026$120.00Overweight
    Morgan Stanley
    1/28/2026$80.00Overweight
    Barclays
    1/20/2026$98.00Hold → Buy
    Canaccord Genuity
    12/3/2025$60.00Outperform → Market Perform
    Leerink Partners
    11/6/2025$61.00Buy → Hold
    Stifel
    9/8/2025$60.00Neutral
    H.C. Wainwright
    More analyst ratings

    $BMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Commercial Officer Hubbard Cristin covered exercise/tax liability with 2,318 shares, decreasing direct ownership by 5% to 42,472 units (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    5/21/26 6:05:02 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief R&D Officer Friberg Gregory R sold $176,682 worth of shares (3,281 units at $53.85), decreasing direct ownership by 6% to 51,818 units (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    5/11/26 5:01:13 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Davis George Eric

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    3/19/26 4:53:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

    Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height Z-score Study demonstrated statistically significant improvement in arm span at week 52 compared to placebo, a key measure linked to functional independenceSafety findings consistent with the established profile in achondroplasia with no new safety signals identifiedSupplemental New Drug Application (sNDA) submission to U.S. Food and Drug Administration (FDA) planned for third quarter, followed by submissions to

    5/20/26 4:20:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

    ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study's other co-primary endpoint and an important clinical measure of change in rickets severity Company is evaluating data to determine next steps SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1

    5/18/26 9:05:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors

    Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen

    5/5/26 7:00:00 AM ET
    $BAX
    $BMRN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

    For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

    6/29/23 6:02:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    SEC Filings

    View All

    SEC Form 10-Q filed by BioMarin Pharmaceutical Inc.

    10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

    5/5/26 1:59:42 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

    5/4/26 4:07:23 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

    4/27/26 8:45:12 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on BioMarin Pharmaceutical with a new price target

    Citigroup initiated coverage of BioMarin Pharmaceutical with a rating of Buy and set a new price target of $75.00

    5/19/26 8:29:23 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on BioMarin Pharmaceutical with a new price target

    Goldman resumed coverage of BioMarin Pharmaceutical with a rating of Neutral and set a new price target of $69.00

    5/11/26 8:29:02 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on BioMarin Pharmaceutical with a new price target

    Morgan Stanley resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $120.00

    4/27/26 8:34:35 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Leadership Updates

    Live Leadership Updates

    View All

    4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors

    Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen

    5/5/26 7:00:00 AM ET
    $BAX
    $BMRN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioMarin Announces Board Leadership Transition

    Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif., April 21, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company's Annual Meeting of Stockholders on June 2, 2026. Mr. Clark will succeed Richard A. Meier, who is retiring after two decades on the Board, and the appointment will become effective immediately following the Annual Meeting. Mr. Clark joined BioMarin's Board in 2025 and brings extensive board, go

    4/21/26 4:23:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Appoints Arpit Davé Chief Digital and Information Officer

    Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy. Mr. Davé will be responsible for reimagining and executing BioMarin's enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders.

    1/12/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Financials

    Live finance-specific insights

    View All

    BioMarin Reports First Quarter 2026 Financial and Operating Results

    First Quarter 2026 Total Revenues Increased Year-over-year to $766 millionIncreased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD® and POMBILITI® + OPFOLDA® to BioMarin's PortfolioConference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Calif., May 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2026. "With the acquisition of Amicus T

    5/4/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

    SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 3424435 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playback I

    4/27/26 7:30:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

    Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO®Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGOAnnounced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify RevenuesBioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Cal

    2/23/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioMarin Pharmaceutical Inc.

    SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    9/30/24 4:29:01 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

    SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    7/10/24 1:14:41 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

    SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    7/8/24 4:32:41 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care